Global Organoids Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Organoids Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Organoids are 3D miniature tissues or organs that are grown in vitro (outside the body) from stem cells or progenitor cells. These organoids can recapitulate key features of their in vivo counterparts and can be used to study the development, function, and disease mechanisms of various organs. The use of organoids has become an important tool for researchers to study human biology and disease and may provide a foundation for developing more effective treatments for various illnesses.

Market Overview:

The latest research study on the global Organoids market finds that the global Organoids market reached a value of USD 79.35 million in 2022. It’s expected that the market will achieve USD 208.55 million by 2028, exhibiting a CAGR of 17.47% during the forecast period.

Increased need for disease modeling

The outbreak of COVID-19 has led to an increased demand for the use of organoids for disease modeling. Researchers have been using organoids to study viruses and their effects on different organs, such as the lungs and intestines. This has led to increased interest in organoid research and development and increased funding for this field of research. For example, during the COVID-19 pandemic, researchers demonstrated the value of human organoids, including intestinal, kidney, and lung organoids, as useful research platforms against SARSCoV-2. These results reflect the positive impact of the enormous investment in organoid-related R&D. A research team at Kyoto University in Japan has successfully created in vitro microbronchial tubes that allow air to enter the alveoli from human iPSCs, a model used to evaluate Avigan against Fujifilm Holdings Corporation's influenza drug and several novel drugs for the treatment of COVID-19. Antiviral drugs.

Increased Interest in Personalized Medicine

Organoids are an important tool for understanding viral pathology, which has prompted researchers to use organoids to develop strategies for the prediction of the COVID-19 situation and its resolution. The COVID-19 outbreak has highlighted the importance of personalized medicine, as different patients can respond very differently to the virus. Organoids are invaluable tools for personalized medicine because they can be derived from patient samples and used to test the efficacy of drugs on an individual basis. This has led to increased interest in organoid research and development for personalized medicine applications.

Technological advancements in organoid research

Technological advancement is one of the significant factors driving the growth of the organoids market. With the continuous development of organoid research technology, more and more diseases can be treated by using organoids for research and drug screening. In terms of efficiency and accuracy, the researchers were able to more accurately simulate human organs and tissues. This means better modeling of disease states during research, leading to improved treatment outcomes. Technological advances are also helping to reduce the cost of producing and maintaining organoids. This means that more organizations and institutions can use this technology for research and treatment. As the market size increases, further cost reduction will also accelerate the market development. Many rare diseases currently have no effective treatments. But as organoid technology improves, researchers will be able to better study these diseases and develop new treatments. This will drive the growth of the market as more and more people will use organoid technology to treat complex diseases. Therefore, through continuous research and innovation, the potential of this market will be continuously released, providing assistance for the treatment of more diseases.

Region Overview:

In 2022, the share of the Organoids market in United States stood at 34.12%.

Company Overview:

StemCell Technologies Inc. of Canada operates as a biotechnology company. The Company specializes in developing cell culture media, cell separation products, instruments, and other reagents for use in stem cell, immunology, cancer, regenerative medicine and cellular therapy research.

Segmentation Overview:

Among different product types, Intestinal Organoid segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Biopharmaceutical Companies segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Organoids market covered in Chapter 3:

Hubrecht Organoid Technology (HUB)
STEMCELL Technologies
DefiniGEN
Cellesce
Qgel
OcellO BV

In Chapter 4 and Chapter 14.2, on the basis of types, the Organoids market from 2018 to 2029 is primarily split into:

Intestinal Organoid
Hepatic Organoid
Pancreatic Organoid
Neural Organoid

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Organoids market from 2018 to 2029 covers:

Biopharmaceutical Companies
Contract Research Organizations
Academics and Research Institutes

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)